We’ve detected that you are using an outdated browser. For Windows users, this site is best experienced using Google Chrome, Firefox, or Microsoft Edge
First and only
FDA-approved treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
Limitations of Use: REXULTI is not indicated as an as needed (“prn”) treatment for agitation associated with dementia due to Alzheimer’s disease
REXULTI® (brexpiprazole) received new indication approval
Read more about the approval and the clinical trials.
Interested in speaking with a representative about REXULTI?
REXULTI representatives serve as a comprehensive resource for medication information, product samples, patient support tools, and savings and coverage details.